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Abstract
Background: Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in 
patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one 
evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results 
of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer.
Methods: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients 
were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 
fractions per week). In dependence of the period when radiotherapy was realized, two different treatment techniques 
were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m2 given on a weekly basis.
Results: The median age was 52 years (range 29-70). Stage IV disease was recognized in 73.2% of the patients. 
Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, 
respectively. A complete composite response was present in 27 patients (65.9%). Median follow-up was 13 months 
(range 7-36). Distant metastases as initial failure occurred in 7 patients (46.7%). The 2-year local relapse-free survival and 
regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival 
rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent 
mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The 
median weight loss at the end of treatment was 12% (range 5-21). The worst grade of late toxicity was most commonly 
pronounced in the skin and in the subcutaneous tissue.
Conclusions: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or 
chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-
modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome 
in patients with advanced hypopharyngeal cancer.
Background
Hypopharyngeal cancer is a rare disease representing
about 0.5% of all human malignancies with an incidence
of less than 1 per 100 000 population and constituting
only 3-5% of all head and neck cancers [1,3]. Hypopha-
ryngeal cancers are often at an advanced stage at diagno-
sis and are associated with a poor prognosis [4,6]. The
reasons for the unfavourable prognosis of hypopharyn-
geal cancers are the strong tendency for extensive submu-
cosal spread, the early occurrence of regional lymphatic
involvement, and the relatively high rate of distant spread
[7,8].
In the 1970s and 1980s, surgery, followed by postopera-
tive radiotherapy was the standard form of therapy for
advanced stage disease [9,10]. This radical approach of
treatment, lead to the loss of natural speech function and
impairment of swallowing ability with a consequent neg-
ative impact on the quality of life, and low cure rates,
reported 5-year survival between 20.0% and 50.0%
[1,2,7,11,12].
The necessity for improvement of survival rates and
preserving organ function resulted in introduction of
chemotherapy as a third treatment modality for patients
with advanced hypoharyngeal cancer. The combined
modality treatment was subject of analysis in two ran-
* Correspondence: istojkovski@gmail.com
1 Department of Head and Neck Cancer, University Clinic of Radiotherapy and 
Oncology, Skopje, Macedonia
† Contributed equally
Full list of author information is available at the end of the articleKrstevska et al. Radiation Oncology 2010, 5:39
http://www.ro-journal.com/content/5/1/39
Page 2 of 11
domized trials. In the study of Beauvillain et al. [13] com-
paring chemotherapy plus radiotherapy with
chemotherapy plus surgery plus radiotherapy, the out-
come was better in the surgical arm. In the randomized
trial conducted by the European Organization for
Research and Treatment of Cancer (EORTC) Head and
Neck Cancer Cooperative group, comparing chemother-
apy plus radiotherapy with surgery plus radiotherapy,
surgical and non-surgical groups had similar 5-year sur-
vival [14]. Both studies did not succeed to give evidence
to support radical surgery for curative treatment for
advanced hypoharynegal cancer. Also, the EORTC 24891
trial [15] demonstrating that laryngeal preservation by
induction chemotherapy followed by definitive radiother-
apy was a safe treatment alternative for patients with T2-
T4 tumours, worked as a good basis for further investiga-
tions of non-surgical management of hypopharyngeal
cancers [16].
Concurrent radiochemotherapy (CRCT) as definitive
treatment for advanced head and neck including cancers
arising from the hypopharynx has been studied in the
past 15 years [17,23].
However, due to the low incidence, hypopharyngeal
cancers grouped with other head and neck cancers usu-
ally represented only smaller subgroups with details of
their treatment being rarely specifically reported [8,16].
The rarity of this disease, and the time needed for data
collection could be accepted as an explanation for the
absence of multicenter randomized clinical trials under-
taken to evaluate the role of CRCT in the treatment of
advanced hypopharyngeal cancer. Despite the fact that
concurrent platinum-based radiochemotherapy was
a d o p t e d  a s  a  s t a n d a r d  o f  c a r e  i n  p a t i e n t s  w i t h  l o c a l l y
advanced HNSCC [24], there is no level one evidence on
best treatment [16], or agreement on treatment for
advanced hypoharyngeal cancer [25].
In order to evaluate the results of non-surgical com-
bined treatment approach we retrospectively analyzed
patients with advanced hypopharyngeal cancer treated
with chemotherapy consisting of cisplatin given on a
weekly basis administered concurrently with external-
beam radiotherapy performed using three dimensional
conformal technique.
Methods
Forty-one consecutive patients with newly diagnosed
advanced stage III-IV squamous cell carcinoma of the
hypopharynx treated with definitive CRCT, from January
2006 to October 2009 at the University Clinic of Radio-
therapy and Oncology in Skopje were analyzed. Pre-treat-
ment evaluations included history, physical examination,
panendoscopy and biopsy, computed tomography (CT)
and/or magnetic resonance imaging (MRI) of the hypo-
pharyngeal and cervical region, chest x-ray, liver ultra-
sound and routine laboratory studies. Patients were
staged according to the 2002 criteria of the American
Joint Committee on Cancer [26]. Written informed con-
sent was obtained from the patients for including in the
study. A copy of the consent is available for review by the
Editor-in-Chief of this journal.
Radiotherapy
The patients were immobilized in supine position with a
thermoplastic head and neck mask. They were treated by
photons with beam qualities of 6 MV and 15 MV and
electrons with energies 9-16 MeV. For the treatment
planning, we used the Eclipse Version 7.3.10, a commer-
cial 3D treatment planning system manufactured by Var-
ian Medical Systems. The CT scanning was made for
each patient in the treatment position with slice thickness
of 0.5 cm.
The gross tumour volume of the primary tumour
(GTVt70) and the metastatic lymph nodes (GTVn70)
were defined as any visible tumour and the gross nodal
disease revealed on imaging studies and/or physical
examination. Neck lymph nodes were considered meta-
static when their smallest axis diameter was greater then
1.0 cm. The clinical target volume (CTVt50) encom-
passed the GTVt70 plus a margin of 1.0-2.0 cm for the
potential microscopic extension of the disease. In
patients with negative neck lymph nodes the CTVn50
included the nodal regions in the neck at levels II-IV. In
patients with clinically involved neck lymph nodes,
CTVn50 included GTVn70 with a margin of 0.5-1.0 cm
and also encompassed retropharyngeal lymph nodes and
nodal regions at levels I-V. Level VI was included in
CTVn50 only in cases when primary tumour invaded
oesophagus. CTV50 was created by integration of
CTVt50 and CTVn50. The planning target volumes were
PTV50 and PTV70. The PTV50 provided a margin of 0.5
cm around CTV50. If there were no positive lymph nodes
in the neck, the PTV70 encompassed the GTVt70 plus a
0.5 cm margin. In patients with nodal disease, the GTV70
was union of GTVt70 and GTVn70, and by adding a mar-
gin of 0.5 cm around it, we obtained PTV70.
The patients were treated by two different treatment
techniques.
The first treatment technique used from January 2005
until January 2008, consisted of three stages. In the first
stage we used semi-fields, where the upper neck was irra-
diated by two opposing lateral semi-fields, and the lower
neck was irradiated by anterior and posterior semi-fields.
For the posterior semi-field we used 15 MV photons, and
for the other fields, 6 MV photons. This stage consisted of
23 fractions, 2 Gy each. In the second stage, comprising
of 2 fractions, 2 Gy each, the lateral fields were reduced
from the dorsal side in order to exclude the spinal cord
from the fields. The dose to the shielded dorsal part of theKrstevska et al. Radiation Oncology 2010, 5:39
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PTV50 was delivered by two lateral electron fields, which
were matched to the photon fields. In the third stage of
the treatment, depending on the position and the volume
of the PTV70, we used arrangements with 2 to 4 photon
fields with beam quality 6 MV in lateral or oblique direc-
tions with occasional use of electron fields, delivering the
remaining 20 Gy in 10 fractions. In this stage the spinal
cord was completely out of field.
The second technique, started from February 2008,
which we have named "oblique photon fields" technique,
consisted of two stages. The idea was to eliminate the use
of electron fields, because of the inconveniences that
occur when matching photon and electron fields (the
cold spots at the surface or the hot spots at greater
depth). In the first stage we delivered 50 Gy in 25 frac-
tions by 4 oblique isocentric photon fields of beam qual-
ity 6 MV. Two of the fields, the anterior ones, were
positioned at gantry angles 300° and 60° and covered the
whole PTV50. The posterior oblique fields were at gantry
angles between 210° and 220° from the right side of the
patient, and between 135° and 145° from the left side. The
spinal cord was shielded in these fields, so they covered
only part of the PTV50. The weight of the posterior fields
was approximately 4 times smaller than the weight of the
anterior ones. The second stage was identical to the third
stage of the first technique.
Chemotherapy
Chemotherapy consisted of cisplatin 30 mg/m2  along
with standard hydration and antiemetic prophylaxis
given to the patients concomitantly with radiation on a
weekly basis. Patients commenced chemotherapy on the
same day as commencing radiotherapy. The full blood
count and biochemistry were checked weekly before che-
motherapy. The criteria of skipping or stopping chemo-
therapy were leucopoenia or experienced severe
mucositis.
Response assessment
Response evaluation was performed three months after
completion of radiochemotherapy by physical examina-
tion, computed tomography CT and/or MRI, and endos-
copy under general anaesthesia. For the primary tumour,
a complete response was defined as complete disappear-
ance of clinical and radiological evidence of disease with a
complete recovery of larynx mobility. Partial response
w a s  d e f i n e d  a s  a  r e g r e s s i o n  o f  a  5 0 %  o r  m o r e  o f  t h e
tumour volume and at least a partial recovery of the lar-
ynx mobility. A complete nodal response was defined as a
complete disappearance of the enlarged lymph nodes. A
partial response was defined as a 50% or more decrease of
the sum of product of perpendicular diameters of all
m e a s u r a b l e  n o d e s  o n  i m a g i n g .  N o  r e s p o n s e  ( N R )  w a s
defined as stable or progressive disease. Complete com-
posite response was considered when both complete pri-
mary and nodal response were achieved.
Follow-up
According to the follow-up policy of our clinic, patients
were examined weekly during radiochemotherapy to
assess treatment-induced toxicity. After the completion
of treatment, all patients were followed up every month
over the first year, every other month in the second year,
and at 3- to 6-month intervals thereafter. A physical
examination and fiberoptic endoscopy were performed
during each follow-up examination. Baseline CT and/or
MRI of the neck were done every 6 months over the first
2 years. Additional investigations were performed when-
ever necessary. Biopsy was performed if there was suspi-
cion of residual or recurrent disease.
Treatment toxicity assessment
Acute reactions induced by radiotherapy were assessed
according to the Acute Radiation Morbidity Scoring Cri-
teria of the Radiation Therapy Oncology Group (RTOG)
[27] and scored on a weekly basis during the course of
treatment and monthly during the first 3 months after the
end of treatment. Chemotherapy-related toxicities were
assessed according to the World Health Organization
(WHO) criteria [28] and were also recorded on a weekly
basis during radiochemotherapy. Late radiotherapy-
related toxicities were evaluated according to the scales of
the European Organization for Research and Treatment
of Cancer/Radiation Therapy Oncology Group (EORTC/
RTOG) [27] and were recorded starting at 6 months after
treatment completion.
Statistical analysis
The end points examined were local relapse-free survival
(LRFS), regional relapse-free survival (RRFS), locore-
gional relapse-free survival (LRRFS), distant metastases-
free survival (DMFS), disease-free survival (DFS), and
OS. LRFS was calculated from the first day of treatment
until the day when a recurrence at the primary site was
first reported, or until the day of the last follow-up.
Patients who did not achieve complete primary response
were assigned a LRFS of 0 months. RRFS was calculated
from the first day of treatment until the day of first occur-
rence of nodal recurrence, or until the day of the last fol-
low-up. Patients without complete nodal response were
assigned a RRFS of 0 months. LRRFS was also evaluated
and calculated from the first day of treatment until the
day of first occurrence of primary and/or neck relapse, or
until the day of the last follow-up. Patients who did not
achieve complete composite response were assigned a
LRRFS of 0 months. DMFS was measured from the start
of treatment to the date of occurrence of clinically
detected DM or to the date of the last follow-up. DFS was
calculated from the first day of treatment to the dateKrstevska et al. Radiation Oncology 2010, 5:39
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when a relapse was first recorded or, in the case of persis-
tent disease, to the date of first follow-up. The end point
of DFS was the occurrence of local, regional or distant
relapse. Patients without evidence of disease were cen-
s o r ed  a t  t h e  d a t e  o f  l as t  f o l l o w -u p .  O S  w a s  c a l c u l a t ed
from the start of treatment until death, or to the most
recent follow-up date. The endpoint for OS was death
from all causes. LRFS, RRFS, LRFS, DMFS, DFS and OS
curves were calculated using the Kaplan-Meier method
[29].
Results
Patients characteristics
The patient characteristics are described in Table 1. The
median age was 52 years (range, 29-70), with a male pre-
dominance (80.5%). The most common primary subsite
was pyriform sinus, present in 78.0% of patients. Locally
advanced primary tumour (T4) was recognized in 25
patients (61.0%). More than one-half of the patients were
diagnosed with metastatic neck nodes. Clinically negative
neck (N0) was present in 17 patients (41.5%). In the whole
number of patients more than two-thirds were seen with
stage IV disease (73.2%). Moderate histological differenti-
ation was present in 17 patients (41.5%). The most fre-
quent symptom at diagnosis was painful swallowing
present in 56.1% of patients.
Compliance of treatment
All treated patients received the full planned dose of
radiotherapy (70 Gy). In 36 patients (87.8%), the overall
treatment time (OTT) for radiotherapy completion was ≤
7 weeks. Photon-electron treatment was realized in 13
patients (31.7%). The rest 28 patients (68.3%) were irradi-
ated using the technique with oblique photon fields.
Twenty-two patients completed all seven cycles of con-
current chemotherapy. Six cycles of cisplatin was given in
16 patients, while 3 patients had less than six cycles of cis-
platin with patients' refusal being the only cause for con-
current chemotherapy cessation. The mean total dose of
cisplatin given was 192 mg/m2 ± 23.2 SD.
Response to treatment
A complete response at the primary site occurred in 28
patients (68.3%). In patients with positive neck the
achieved complete response rate was 36.6%. A complete
composite response was present in 27 patients (65.9%). A
partial composite response was registered in 14 patients
(34.1%). Of those, only one patient had a complete
response of the primary tumor and a partial response of
the nodal disease. In all other patients, there was a partial
response at the primary site and at the neck region.
Patterns of failure
Median patient follow-up at the commencement of the
analysis was 13 months (range 7-36). Local recurrence
was developed in 3 patients, 1 patient developed regional
recurrence, and 4 patients developed both. Distant
metastases were the predominant initial failure occurred
in 7 patients and accounting for 46.7% of the cases who
manifested a relapse of the disease. Distant metastases
were also developed in 3 patients who had not achieved
complete composite response following treatment.
Hence, the overall incidence of distant metastases was
24.4% (10/41). Not one patient had an identification of
distant metastatic disease preceded by the occurrence of
local and/or regional recurrence. The most frequent site
of distant metastases (80.0%) was the lungs. The median
time to development of local recurrence was 12 months
(range 4-19). Regional recurrence developed as a single
event occurred at 7 months after beginning of treatment.
The median time to occurrence of locoregional recur-
rence and distant metastases was 10.5 months (range 9-
19) and 9.5 months (range 4-21), respectively.
Survival
A t the time of analysis, 19 patients were alive. Among
those, 1 patient had recurrence in the neck nodes, 1
patient had recurrence of the primary tumour, 2 patients
had recurrence of the primary and of the nodal disease, 4
patients had distant metastases, and 11 patients were
alive free of disease. During the follow-up period, due to
tumor progression, a tracheotomy had been performed in
8 patients, 3 patients required a placement of a feeding
tube, and in other 3 patients a gastrostomy had been per-
formed. Death was disease-related in vast majority of
patients (21/22). Three patients had died of local or
locoregional recurrence, 1 patient had unknown cause of
death, 12 patients had died of the progression of their
persistent disease, 3 patients had died of distant metasta-
ses, and 3 patients had died due to both persistent disease
and distant metastases.
The 2-year LRFS and RRFS survival rates were 55.2%
and 75.8%, respectively (Figure 1). The median duration
of LRFS was 10 months (range 0-36) and the median
duration of RRFS was 12 months (range 0-36). The
LRRFS at 2 years was 51.3% (Figure 1). The median dura-
tion of LRRFS was 10 months (range 0-36). The DMFS at
2 years was 64.7% (Figure 2). The median duration of
DMFS was 12 months (range 4-36). The 2-year DFS and
OS survival rates were 29.3% and 32.8%, respectively (Fig-
ure 3). The median duration of DFS was 9 months (range
3-36) and the median duration of OS was 14 months
(range 7-36).Krstevska et al. Radiation Oncology 2010, 5:39
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Toxicity
The acute toxic effects of treatment are illustrated in
Table 2. Grade 2 skin reaction (deep hyperpigmentation
and dry desquamation) was developed in 75.6% of
patients. Grade 3 skin reaction (moist desquamation) was
manifested in only 4.9% of patients. Grade 2 mucous
membrane reaction (patchy mucositis) was developed in
48.8% of patients. Similar proportion (46.3%) of patients
developed confluent mucositis (grade 3 mucous mem-
brane reaction). The most common grade of acute reac-
tion in the pharynx was grade 2, experienced in 73.2% of
patients. The most frequent haematological toxicity was
leucopenia grade 1, present in 70.7% of patients. The
median weight loss at the end of radiochemotherapy was
Table 1: Patients characteristics (n = 41).
Characteristics No. of patients %
Gender
Male 33 80.5
Female 8 19.5
Age, years
Median 52
Range 29-70
Performance status (ECOG)
02 6 6 3 . 4
11 5 3 6 . 6
Subsite
Pyriform sinus 32 78.0
Posterior pharyngeal wall 5 12.2
Postcricoid area 4 9.8
T stage
T3 16 39.0
T4 25 61.0
N stage
N0 17 41.5
N1 6 14.6
N2 12 29.3
N3 6 14.6
Stage
III 11 26.8
IV 30 73.2
Histological differentiation
Good 6 14.6
Moderate 17 41.5
Poor 16 39.0
Unknown 2 4.9
Symptoms at diagnosis
A sore throat 3 7.3
Ear pain 2 4.9
Lump in the neck 8 19.5
Painful swallowing 23 56.1
Change in voice 5 12.2
ECOG, Eastern Cooperative Oncology Group.Krstevska et al. Radiation Oncology 2010, 5:39
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Figure 1 Kaplan-Meier curves of local relapse-free survival, regional relapse-free survival and locoregional relapse-free survival.
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Figure 2 Kaplan-Meier curve of distant metastases-free survival.
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12.0% (range 5-21). Late normal tissue reactions are listed
in Table 3. The worst grade of late toxicity (grade 2) was
most commonly found in the skin (34.1% of patients) and
in the subcutaneous tissue (65.9% of patients).
Discussion
Hypopharyngeal cancer is a head and neck neoplasm
with one of the most unfavourable prognosis. Although
there is no level one evidence on best treatment for
advanced hypopharyngeal cancer [16], considering the
fact that vast majority of patients presenting with
advanced stage disease are inoperable, unfit for opera-
tion, or refuse surgery, we found the use of chemotherapy
and radiotherapy administered concomitantly as a ratio-
nal treatment option for this patient category.
The achieved rate of complete composite response in
our study was 65.7%. This result is comparable with the
results observed in other studies investigating the effec-
tiveness of combined radiotherapy and chemotherapy for
advanced hypopharyngeal carcinoma. Yoon et al. [30]
reported a complete response rate of 82.0% in the group
of 28 patients treated with induction chemotherapy fol-
lowed by CRCT. In the retrospective study comparing the
results of treatment of locally advanced hypopharyngeal
cancer with two different protocols, Hung et al. [4] found
the response rate of 77.0% in 38 patients treated with
definitive CRCT followed by adjuvant chemotherapy.
The results of our study demonstrated that grade 3
acute response of the mucous membrane was present in
almost one half of the patients (48.8%). This corresponds
with the findings of other authors [4,31]. The rate of
grade 2 weight loss registered in our study was 53.6%, but
we did not observe increased rates of chemotherapy-
related haematological toxic effects. Although the inci-
dence of development of confluent mucositis was
expected to be increased with CRCT and was thought to
affect treatment course, there was no treatment interrup-
tion occurring in the event of swallowing disturbance in
our study. Also, none of the patients had to discontinue
treatment as a consequence of haematological toxicity.
Using three dimensional conformal radiotherapy and
concomitant weekly cisplatin we succeeded to deliver the
prescribed dose of 70 Gy in all the patients, and there
were only 3 patients receiving less than six cycles of con-
current chemotherapy.
Figure 3 Kaplan-Meier curves of disease-free survival and overall survival.
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I n  o u r  s t u d y  l o c o r e g i o n a l  r e c u r r e n c e  o c c u r r e d  i n  8
patients. Distant metastases as an initial failure occurred
in 7 patients. The overall incidence of distant metastases
was 24.4%. Similar findings were obtained by other
authors. In the study of Hung et al. [4], distant metastases
also occurred in 24.0% of patients treated with CRCT. In
the retrospective analysis of Elias et al. [32] on treatment
results of carcinoma of the pyriform sinus, 32.0% of
patient population developed distant metastases. The fre-
quency of DM of 46.7% as first site of failure in our study
was ten fold higher compared to the results reported by
Johansen et al. [2]. Although it is generally considered
that locoregional control of head and neck cancer repre-
sents an important factor for development of distant
metastases, we did not observe any distant metastases
development preceded by occurrence of locoregional
r ecu rr e n c e .  T h is  da t a  l ed  us  t o  as s u m e  t h a t  t h e r e  h a d
Table 2: Acute toxicity induced by concurrent chemoradiotherapy.
Grade of reaction (% of 41 patients)
T o x i c i t y 0123
Acute normal tissue reactions according to RTOG criteria
Organ/Tissue
Skin 0 19.5 75.6 4.9
Mucous membrane 0 4.9 48.8 46.3
Salivary gland 0 34.1 61.0 4.9
Pharynx 0 21.9 73.2 4.9
Larynx 24.4 36.6 39.0 0
Acute toxicity according to WHO criteria
Nonhematological
Nausea 46.3 51.2 2.4 0
Vomiting 63.4 34.1 2.4 0
Weight loss 0 43.9 53.6 2.4
Hematological
Leucopenia 19.5 70.7 9.8 0
Anemia 36.6 56.1 7.3 0
Thrombocytopenia 51.2 48.8 0 0
RTOG, Radiation Therapy Oncology Group; WHO, World Health Organization.
* Because of rounding, not all percentages total 100.
Table 3: Late normal tissue reactions.
Grade of reaction (% of 41 patients)
Organ/Tissue 0 1 2
Skin 2.4 63.4 34.1
Subcutaneous tissue 0 34.1 65.9
Mucous membrane 0 87.8 12.2
Salivary gland 9.8 75.6 14.6
* Because of rounding, not all percentages total 100.Krstevska et al. Radiation Oncology 2010, 5:39
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been a high probability for the presence of occult distant
metastases at the time of initial patients screening.
The LRRFS at 2 years revealed in our study was 51.3%, a
result that differs from the 2-year locoregional progres-
sion-free survival rate for patients with hypopharyngeal
cancer of 73.0% in the study of Lee et al. [31]. In the study
of Yoon et al. [30], the 3-year locoregional control for the
group treated with CRCT was 52.0%. Johansen et al. [2] in
their study of treatment results in 138 patients with hypo-
pharyngeal carcinoma reported low rates of locoregional
control at 5 years (25.0%). The 2-year DMFS rate in our
study was 64.7%. In contrast, Lee et al. [31] reported rate
of 2-year freedom from distant metastasis of 92.0%. In the
study of Kim et al. [33] on treatment results in advanced
hypopharyngeal carcinoma according to treatment
modalities, the 5-year DMFS rate in the group treated
with induction chemotherapy and radiotherapy was
82.4%. The rate of 2-year DFS in our study is similar to
the 3-year DFS rate of 28.8% for stage IV hypoharyngeal
cancer in the study of Gupta et al. [34]. In the study of
Hung et al. [4], there was also a very low rate of 3-year
DFS (21.0%). The OS rate at 2 years in our study was
32.8% and was lower than the reported 2-year OS rate of
53.0% in the study of Lee et al. [31]. A higher rate of OS
was also reported by Yoon et al. [30] and by Hung et al.
[4] (3-year OS rate of 54.0% and 43.0%, respectively).
Considering the rates of LRRFS, DMFS, DFS, and OS in
our study, and comparing them with the rates observed in
other clinical studies, we must conclude that irrespec-
tively to the combined treatment modality used (CRCT,
induction chemotherapy with radiotherapy, or CRCT fol-
lowed by adjuvant chemotherapy), the results were far
from being satisfactory. At this point, the necessity of
locoregional control improvement and decrease of dis-
tant metastases as critical factors for increase in DFS and
OS survival must be taken in consideration. The imple-
mentation of intensity-modulated radiotherapy (IMRT)
as sophisticated radiotherapy technique combined with
concomitant chemotherapy, the use of altered fraction-
ation regimens, the use of intensified concurrent
radiochemotherapy, the adoption of sequential therapy,
and the administration of targeted therapy concurrently
with conventional or altered fractionation, could be con-
sidered as combinations of treatment factors able to con-
tribute to the ultimate outcome of patients with advanced
hypoharyngeal cancer.
The possibility for higher dose delivery in the tumor
while sparing critical structures by using IMRT are rea-
sonably expected to enable improvement in locoregional
control in advanced hypopharyngeal cancer.
The improvement of locoregional control in advanced
head and neck cancer has been achieved by the use of
altered fractionated radiotherapy [35,38]. In the meta-
analysis of 15 trials examining the role of altered fraction-
ation radiotherapy in head and neck cancer, Bourhis et al.
[39] reported that altered fractionation improves 5-year
local control by 6.4% and 5-year OS by 3.4% compared
with conventionally fractionated radiotherapy with sig-
nificantly higher benefit seen with hyperfractionated
radiotherapy. The comparison of conventionally fraction-
ated radiotherapy with altered fractionation radiotherapy
in the German meta-analysis of 32 randomized trials on
patients with squamous cell carcinoma of the head and
neck (oral cavity, oropharynx, hypopharynx, and larynx)
also showed that hyperfractionation led to a significant
improvement of OS if radiotherapy was used as single
treatment modality [40].
Regarding the confirmed role of CRCT as a recom-
mendable treatment option in advanced head and neck
cancer [41,42] and considering the confirmed advantage
of altered fractionation over conventionally fractionated
radiotherapy, the intensified CRCT (altered fractionation
and concurrent chemotherapy) should be also considered
as another attempt to further improve both locoregional
control and OS. In the prospective randomized clinical
study in advanced oropharyngeal, oral cavity and hypo-
p h a r y n g e a l  c a n c e r  c o n d u c t e d  b y  B u d a c h  e t  a l .  [ 4 3 ] ,
altered fractionation radiotherapy with CRCT was found
superior to altered fractionation radiotherapy alone. The
analysis on altered fractionation radiotherapy in combi-
nation with concurrent chemotherapy in the German
meta-analysis resulted in an OS benefit of 12.0% com-
pared to altered fractionation radiotherapy alone, that
was similar to the survival benefit achieved with conven-
tionally fractionated radiotherapy with concurrent che-
motherapy, compared with conventionally fractionated
radiotherapy alone [40]. These results suggested that the
use of concurrent chemotherapy enabled a significant
improvement in OS, regardless of the fractionation regi-
men employed.
The development of distant metastases during follow-
up period represents a serious problem reflecting nega-
tively on DFS and OS in patients with advanced hypopha-
ryngeal cancer. The adoption of CRCT as a standard of
care for patients with locally advanced HNSCC is associ-
ated with improved locoregional control and OS com-
pared to radiotherapy alone [39,40], and its efficacy to
decrease the rate of distant metastatic disease has been
also confirmed in phase III trials that have tested this
treatment option [23,44,45].
Targeted therapy in head and neck cancer is closely
connected to the use of cetuximab, an anti-Epidermal
Growth Factor Receptor (EGFR) antibody therapy, con-
firmed to be effective in combination with radiotherapy
in previously untreated patients in a single controlled
clinical trial [46,47]. The recently started phase III trial
(RTOG 0522) exploring cisplatin-based CRCT with orKrstevska et al. Radiation Oncology 2010, 5:39
http://www.ro-journal.com/content/5/1/39
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without cetuximab is expected to clarify the role of cetux-
imab in integrated radiochemotherapy association [48].
Conclusions
Taking into account the unsatisfactory results achieved
using CRCT in our study, we strongly advocate an
emerged change of therapeutic approach in patients with
advanced hypopharyngeal cancer.
Concerning the radiotherapy technique in the treat-
ment of hypopharyngeal cancer, we recommend the
adoption of IMRT in the routine clinical practice because
of its more conformal dose distribution with steep gradi-
ents between PTV and critical structures.
We also consider that hyperfractionation, in the pres-
ence of sufficient radiotherapy resources, could be imple-
mented as treatment modality with beneficial impact on
OS in patients with advanced hypopharyngeal cancer.
Accepting platinum-based CRCT, in the absence of
conclusive arguments supporting exact schedule of cispl-
atin administration, we advocate the use of weekly cispla-
tin considering it as the simplest solution that provides
radiosensitizing effect to a larger proportion of the radio-
therapy dose and leads to less chemotherapy induced tox-
icity.
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